Evidence map›Paper›PMID 21317931›Full record

ArticleOncogene2011

The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.

L M Privette Vinnedge, R McClaine, P K Wagh, K A Wikenheiser-Brokamp, S E Waltz, S I Wells

Abstract read
In one paragraph

Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Potential ofMolecular and clinical oncology · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Role of the DEK oncogene in the development of squamous cell carcinoma.International journal of clinical oncology · 2020
    Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

L M Privette VinnedgeDepartment of Hematology and Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
R McClaine
P K Wagh
K A Wikenheiser-Brokamp
S E Waltz
S I Wells
University of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · US

Funding

ROLE OF ANGPTL4, AN ANGIOGENIC MEDIATOR, IN ARTHRITISP30AR047363 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI THOMPSON, SUSAN D · 2001 to 2015
$9.2M
Role of Rb Family in Lung Epithelial Response to InjuryR01HL079193 · NHLBI · UNIVERSITY OF CINCINNATI · PI WIKENHEISER-BROKAMP, KATHRYN ANN · 2005 to 2013
$3.4M
Role and Regulaton of the Human DEK Proto-OncogeneR01CA116316 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI WELLS, SUSANNE I · 2006 to 2016
$2.9M
The Ron Receptor in Mammary Gland BiologyR01CA100002 · NCI · UNIVERSITY OF CINCINNATI · PI WALTZ, SUSAN E · 2004 to 2008
$1.5M
Training program in hematologic and oncologic diseasesT32HL091805 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI ZHENG, YI · 2008 to 2012
$835k
The role of DEK in breast cancer development and therapyF32CA139931 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI PRIVETTE VINNEDGE, LISA M. · 2009 to 2010
$98k
Ron Receptor Tyrosine Kinase Signaling in Breast CancerI01BX000803 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI WALTZ, SUSAN E · 2011 to 2025
–
BLRD VA I01 BX000803NCI NIH HHS CA100002NCI NIH HHS CA116316NCI NIH HHS F32 CA139931NCI NIH HHS F32CA139931NCI NIH HHS R01 CA100002NCI NIH HHS R01 CA116316NHLBI NIH HHS HL079193NHLBI NIH HHS R01 HL079193NHLBI NIH HHS T32 HL091805NHLBI NIH HHS T32HL091805NIAMS NIH HHS AR-47363NIAMS NIH HHS P30 AR047363
6 · The paper itself

Abstract

Breast cancer is a major cause of cancer-related deaths in American women; therefore, the identification of novel breast cancer-related molecules for the discovery of new markers and drug targets remains essential. The human DEK gene, which encodes a chromatin-binding protein and DNA topology regulator, is upregulated in many types of cancer. DEK has been implicated as an oncogene in breast cancer based on mRNA expression studies, but its functional significance in breast cancer growth and progression has not yet been tested directly. We demonstrate that DEK is highly expressed in breast cancer cells compared with normal tissue, and functionally important for cellular growth, invasion and mammosphere formation. DEK overexpression in non-tumorigenic MCF10A cells resulted in increased growth and motility, with a concomitant downregulation of E-cadherin. Conversely, DEK knockdown in MCF7 and MDA-MB-468 breast cancer cells resulted in decreased growth and motility with upregulation of E-cadherin. The use of DEK-proficient and -deficient breast cancer cells in orthotopic xenografts provided further in vivo evidence that DEK contributes to tumor growth. Activation of the β-catenin signaling pathway is important for normal and cancer stem cell character, growth and metastasis. We show that DEK expression stimulated, and DEK knockdown repressed β-catenin nuclear translocation and activity. Importantly, the expression of constitutively active β-catenin rescued breast cancer invasion defects of DEK knockdown cells. Together, our data indicate that DEK expression stimulates the growth, stem cell character and motility of breast cancer cells, and that DEK-dependent cellular invasion occurs at least in part via β-catenin activation.

Indexed as

Proto-OncogenesAnimalsbeta CateninBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalChromosomal Proteins, Non-HistoneFemaleHumansMiceNeoplasm InvasivenessNeoplastic Stem CellsOncogene ProteinsPoly-ADP-Ribose Binding Proteinsbeta CateninChromosomal Proteins, Non-HistoneCTNNB1 protein, humanDEK protein, humanOncogene ProteinsPoly-ADP-Ribose Binding Proteins

Identifiers

PMID21317931
PMCPMC3117026
OpenAlexW1975735776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.